NCT05657301View on ClinicalTrials.gov

Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

KH631

KH631: AAV vector containing a coding sequence for an anti-VEGF protein

Trial Locations (7)

38138

RECRUITING

Kanghong Investigative Site, Germantown

60439

RECRUITING

Kanghong Investigative Site, Lemont

75231

NOT_YET_RECRUITING

Kanghong Investigative Site, Dallas

85016

RECRUITING

Kanghong Investigative Site, Phoenix

89502

NOT_YET_RECRUITING

Kanghong Investigative Site, Reno

02114

RECRUITING

Kanghong Investigative Site, Boston

08034

RECRUITING

Kanghong Investigative Site, Cherry Hill

All Listed Sponsors
lead

Chengdu Origen Biotechnology Co., Ltd.

INDUSTRY